HuGE Literature Finder
Records
1
-
30
| Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLC. Annals of oncology : official journal of the European Society for Medical Oncology 2023 1 . Mok T S K, Lopes G, Cho B C, Kowalski D M, Kasahara K, Wu Y-L, de Castro G, Turna H Z, Cristescu R, Aurora-Garg D, Loboda A, Lunceford J, Kobie J, Ayers M, Pietanza M C, Piperdi B, Herbst R |
| CYP3A5 Expressor Genotype of the Transplanted Kidney Increases the Risk of Preterm Graft Loss and Acute Rejection. Nephron 2023 1 1-9. Warzyszy?ska Karola, Zawistowski Micha?, Karpeta Edyta, Ja?brzykowska Agnieszka, Kosieradzki Maci |
| Estimated glomerular filtration rate in Brazilian adults with sickle cell disease: results from the REDS-III multicenter cohort study. Annals of hematology 2023 3 . Belisário André Rolim, Simões E Silva Ana Cristina, Moura Isabel Cristina Gomes, Carneiro-Proietti Anna Bárbara, Sabino Ester Cerdeira, Loureiro Paula, Máximo Cláudia, Flor-Park Miriam V, Rodrigues Daniela de Oliveira Werneck, Ozahata Mina Cintho, Mota Rosimere Afonso, Dinardo Carla Luana, Kelly Shannon, Custer Brian, |
| Exploratory analysis of immunochemotherapy compared to chemotherapy after EGFR-TKI in non-small cell lung cancer patients with EGFR mutation: A multicenter retrospective study. Thoracic cancer 2023 3 . Hata Tae, Sakaguchi Chikara, Hirano Keita, Kobe Hiroshi, Ishida Masaki, Nakano Takayuki, Tachibana Yusuke, Tamiya Nobuyo, Shiotsu Shinsuke, Takeda Takayuki, Yamada Tadaaki, Yokoyama Toshihide, Tsuchiya Michiko, Nagasaka Yuk |
| Influence of EGFR mutation status and PD-L1 expression in stage III unresectable non-small cell lung cancer treated with chemoradiation and consolidation durvalumab. Asia-Pacific journal of clinical oncology 2023 3 . Nindra Udit, Shahnam Adel, Stevens Samuel, Pal Abhijit, Nagrial Adnan, Lee Jenny, Yip Po Yee, Adam Tamiem, Boyer Michael, Kao Steven, Bray Victor |
| Monitoring of T790M in plasma ctDNA of advanced EGFR-mutant NSCLC patients on first- or second-generation tyrosine kinase inhibitors. BMC cancer 2023 3 23 (1): 234. Huang Chun-Ta, Lin Chih-An, Su Te-Jen, Yang Ching-Yao, Tsai Tzu-Hsiu, Hsu Chia-Lin, Liao Wei-Yu, Chen Kuan-Yu, Ho Chao-Chi, Yu Chong-J |
| The efficacy and safety of PD-1 inhibitors for EGFR-mutant non-small cell lung cancer after tyrosine kinase inhibitor failure: a retrospective real-world cohort study. Annals of translational medicine 2023 2 11 (3): 157. Zhou Chunyang, Wang Zijian, Fu Chengrui, Tao Hengmin, Liu Chengx |
| Uses of Vascular Endothelial Growth Factor C as a Lung Adenocarcinoma Prognostic Biomarker. World journal of oncology 2023 3 14 (1): 51-59. Chen Shi, Pan Ting Yu, Wu Xiao, Li Tian, Wei Yu, He Hai Lang, Zhou Xian Mei, Wang Qian, Zhu Ji Pi |
| Correlations of switch/sucrose nonfermentable complex mutations with clinical outcomes in advanced non-small cell lung cancer. Thoracic cancer 2022 Sep . Chang Geyun, Li Weihua, Bai Hua, Duan Jianchun, Wang Zhijie, Du Xinyang, Yu Ruofei, Wang Yaxi, Wang Minghao, Zhu Yixiang, Zhang Xue, Li Li, Wan Rui, Wang J |
| Tumoral PD-L1 does not impact time to treatment discontinuation in EGFR mutated non-small cell lung cancer patients treated with EGFR tyrosine kinase inhibitor-a Danish cohort study. Translational lung cancer research 2022 Sep 11 (9): 1796-1808. Dissing Julie Gabe, Ulhøi Maiken Parm, Sorensen Boe Sandahl, Meldgaard Pet |
| A Randomized Phase 2 Trial of Nivolumab Versus Nivolumab-Ipilimumab Combination in EGFR-Mutant NSCLC. JTO clinical and research reports 2022 11 3 (12): 100416. Lai Gillianne G Y, Yeo Jia Chi, Jain Amit, Zhou Siqin, Pang Mengyuan, Alvarez Jacob J S, Sim Ngak Leng, Tan Aaron C, Suteja Lisda, Lim Tze Wei, Guo Yu Amanda, Shen Meixin, Saw Stephanie P L, Rohatgi Neha, Yeong Joe P S, Takano Angela, Lim Kiat Hon, Gogna Apoorva, Too Chow Wei, Da Zhuang Kun, Tan Wan Ling, Kanesvaran Ravindran, Ng Quan Sing, Ang Mei Kim, Rajasekaran Tanujaa, Wang Lanying, Toh Chee Keong, Lim Wan-Teck, Tam Wai Leong, Tan Sze Huey, Skanderup Anders M J, Tan Eng-Huat, Tan Daniel S |
| A retrospective study for prognostic significance of type II diabetes mellitus and hemoglobin A1c levels in non-small cell lung cancer patients treated with pembrolizumab. Translational lung cancer research 2022 9 11 (8): 1619-1630. Shen Yinchen, Li Jiaqi, Qiang Huiping, Lei Yuqiong, Chang Qing, Zhong Runbo, Stella Giulia Maria, Gelsomino Francesco, Kim Yeon Wook, Abed Afaf, Qian Jialin, Chu Tianqi |
| Actionable mutations in non-small cell lung cancer in patients at hospital de Especialidades Eugenio Espejo, Ecuador 2017-2020. Drug metabolism and personalized therapy 2022 12 . Fernández Freire Miguel Ángel, Gálvez Salazar Gabriela Isabel, Scudeler Mariana Meira, Rodrigues-Soares Fernanda, Jaramillo Koupermann Gabriela Fernanda, Moreno Ocampo Andrea Pao |
| An open label, safety study of Asian patients with advanced non-small-cell lung cancer receiving second-line nivolumab monotherapy (CheckMate 870). Therapeutic advances in medical oncology 2022 11 14 17588359221138380. Lu Shun, Cheng Ying, Zhou Jianying, Wang Mengzhao, Zhao Jun, Wang Baocheng, Chen Gongyan, Feng Jifeng, Ma Zhiyong, Wu Lin, Wang Changli, Ma Kewei, Zhang Shucai, Liang Jun, Song Yong, Wang Jie, Wu Yi-Long, Li Ang, Huang Yizhi, Chang Jianh |
| Apolipoprotein L1 Genotypes and the Association of Urinary Potassium Excretion with CKD Progression. Clinical journal of the American Society of Nephrology : CJASN 2022 11 17 (10): 1477-1486. Ilori Titilayo O, Liu Jing, Rodan Aylin R, Verma Ashish, Mills Katherine T, He Jiang, Winkler Cheryl A, Dupuis Josée, Anderson Cheryl A M, Waikar Sushrut |
| Clinical phenotypes and long-term outcome of kidney involvement in Erdheim-Chester histiocytosis. Kidney international 2022 11 103 (1): 177-186. Chazal Thibaud, Pegoraro Francesco, Manari Gaia, Bettiol Alessandra, Maniscalco Valerio, Gelain Elena, Charlotte Frédéric, Mazor Roei D, Renard-Penna Raphaele, Amoura Zahir, Cohen-Aubart Fleur, Haroche Julien, Izzedine Hassan, Vaglio Augus |
| Clinical predictors of treatment efficacy and a prognostic nomogram in patients with lung adenocarcinoma receiving immune checkpoint inhibitors: a retrospective study. Journal of thoracic disease 2022 11 14 (10): 4096-4112. Hu Fang, Peng Jin, Niu Yanjie, Mao Xiaowei, Zhao Yizhuo, Jiang Liy |
| Clinical significance of intrarenal vascular lesions in non-hypertensive patients with IgA nephropathy. Journal of nephrology 2022 12 . Huang Ziyuan, Hu Ya, Chen Bo, Liang Yan, Li Duo, Qiu Wenxian, Zhang Ji, Chen Chaoshe |
| High levels of AXL expression in untreated EGFR-mutated non-small cell lung cancer negatively impacts the use of osimertinib. Cancer science 2022 9 114 (2): 606-618. Yoshimura Akihiro, Yamada Tadaaki, Serizawa Masakuni, Uehara Hisanori, Tanimura Keiko, Okuma Yusuke, Fukuda Akito, Watanabe Satoshi, Nishioka Naoya, Takeda Takayuki, Chihara Yusuke, Takemoto Shinnosuke, Harada Taishi, Hiranuma Osamu, Shirai Yukina, Shukuya Takehito, Nishiyama Akihiro, Goto Yasuhiro, Shiotsu Shinsuke, Kunimasa Kei, Morimoto Kenji, Katayama Yuki, Suda Kenichi, Mitsudomi Tetsuya, Yano Seiji, Kenmotsu Hirotsugu, Takahashi Toshiaki, Takayama Koic |
| Icotinib, an EGFR tyrosine kinase inhibitor, as adjuvant therapy for patients with stage IIA-IIIA EGFR-mutant non-small-cell lung adenocarcinoma: a multicenter, open-label, single-arm, phase II study (ICAPE). Investigational new drugs 2022 11 . Qian Kun, Chen Qi-Rui, He Ming, Wang Zi-Tong, Liu Yu, Liang Hua-Gang, Su Zhi-Yong, Cui Yu-Shang, Liu Li-Jun, Zhang |
| Impact of gender on response to immune checkpoint inhibitors in patients with non-small cell lung cancer undergoing second- or later-line treatment. Translational lung cancer research 2022 10 11 (9): 1866-1876. Choi Myeong Geun, Choi Chang-Min, Lee Dae Ho, Kim Sang-We, Yoon Shinkyo, Ji Wonjun, Lee Jae Che |
| Landscape of Genomic Alterations and PD-L1 Expression in Early-Stage Non-Small-Cell Lung Cancer (NSCLC)-A Single Center, Retrospective Observational Study. International journal of molecular sciences 2022 10 23 (20): . Stephan-Falkenau Susann, Streubel Anna, Mairinger Thomas, Kollmeier Jens, Misch Daniel, Thiel Sebastian, Bauer Torsten, Pfannschmidt Joachim, Hollmann Manuel, Wessolly Michael, Blum Torsten Gerri |
| Low expression of the metabolism-related gene SLC25A21 predicts unfavourable prognosis in patients with acute myeloid leukaemia. Frontiers in genetics 2022 10 13 970316. Wang Wenjun, Liang Qian, Zhao Jingyu, Pan Hong, Gao Zhen, Fang Liwei, Zhou Yuan, Shi J |
| Optimal Treatments for NSCLC Patients Harboring Primary or Acquired MET Amplification. Technology in cancer research & treatment 2022 9 21 15330338221128414. Sun Dantong, Tao Junyan, Yan Weihua, Zhu Jingjuan, Zhou Hai, Sheng Yingying, Xue Chaofan, Li Hong, Hou Hel |
| PD-L1 Expression is not a Predictive Factor for Recurrence in Resected Non-small Cell Lung Cancer. Lung 2022 12 201 (1): 95-101. Motono Nozomu, Mizoguchi Takaki, Ishikawa Masahito, Iwai Shun, Iijima Yoshihito, Uramoto Hideta |
| PD-L1 score as a prognostic biomarker in asian early-stage epidermal growth factor receptor-mutated lung cancer. European journal of cancer (Oxford, England : 1990) 2022 11 178 139-149. Saw Stephanie P L, Ng Win Pin, Zhou Siqin, Lai Gillianne G Y, Tan Aaron C, Ang Mei-Kim, Lim Wan-Teck, Kanesvaran Ravindran, Ng Quan Sing, Jain Amit, Tan Wan Ling, Rajasekaran Tanujaa, Chan Johan W K, Teh Yi Lin, Pang Mengyuan, Yeo Jia-Chi, Takano Angela, Ong Boon-Hean, Tan Eng-Huat, Tan Sze Huey, Skanderup Anders J, Tan Daniel S |
| Safety and Efficacy of CYP2C19 Genotype-Guided Escalation of P2Y Inhibitor Therapy After Percutaneous Coronary Intervention in Chronic Kidney Disease: a Post Hoc Analysis of the TAILOR-PCI Study. Cardiovascular drugs and therapy 2022 11 . Mathew Roy O, Sidhu Mandeep S, Rihal Charanjit S, Lennon Ryan, El-Hajjar Mohammed, Yager Neil, Lyubarova Radmila, Abdul-Nour Khaled, Weitz Steven, O'Cochlain D Fearghas, Murthy Vishakantha, Levisay Justin, Marzo Kevin, Graham John, Dzavik Vlad, So Derek, Goodman Shaun, Rosenberg Yves D, Pereira Naveen, Farkouh Michael |
| The cuproptosis-related signature associated with the tumor environment and prognosis of patients with glioma. Frontiers in immunology 2022 13 998236. Wang Weichen, Lu Zhichao, Wang Maoyu, Liu Zongheng, Wu Bing, Yang Chengkai, Huan He, Gong Peip |
| The effect of EGFR-TKIs on survival in advanced non-small-cell lung cancer with EGFR mutations: A real-world study. Cancer medicine 2022 11 . Yu Xiaoqing, Si Jinfei, Wei Jingwen, Wang Yanling, Sun Yan, Jin Jianan, Zhang Xiaoyan, Ma Tonghui, Song Zheng |
| Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non-Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01). Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2022 10 41 (3): 651-663. Wang Zhijie, Wu Lin, Li Baolan, Cheng Ying, Li Xiaoling, Wang Xicheng, Han Liang, Wu Xiaohong, Fan Yun, Yu Yan, Lv Dongqing, Shi Jianhua, Huang Jianjin, Zhou Shaozhang, Han Baohui, Sun Guogui, Guo Qisen, Ji Youxin, Zhu Xiaoli, Hu Sheng, Zhang Wei, Wang Qiming, Jia Yuming, Wang Ziping, Song Yong, Wu Jingxun, Shi Meiqi, Li Xingya, Han Zhigang, Liu Yunpeng, Yu Zhuang, Liu An-Wen, Wang Xiuwen, Zhou Caicun, Zhong Diansheng, Miao Liyun, Zhang Zhihong, Zhao Hui, Yang Jun, Wang Dong, Wang Yingyi, Li Qiang, Zhang Xiaodong, Ji Mei, Yang Zhenzhou, Cui Jiuwei, Gao Beili, Wang Buhai, Liu Hu, Nie Lei, He Mei, Jin Shi, Gu Wei, Shu Yongqian, Zhou Tong, Feng Jian, Yang Xinmei, Huang Cheng, Zhu Bo, Yao Yu, Tang Xiongwen, Yu Jianjun, Maher Ellen, Feng Hui, Yao Sheng, Keegan Patricia, Wang J |
- Page last reviewed:Feb 1, 2023
- Page last updated:Mar 30, 2023
- Content source: